Log In
Print
BCIQ
Print
Print this Print this
 

Captisol-Enabled Clopidogrel IV, clopidogrel (MDCO-157)

  Manage Alerts
Collapse Summary General Information
Company Ligand Pharmaceuticals Inc.
DescriptionIV formulation of clopidogrel
Molecular Target Purinergic receptor P2Y G protein-coupled 12 (P2RY12) (P2Y12)
Mechanism of ActionPurinergic receptor P2Y G protein-coupled 12 (P2RY12) (P2Y12) antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationAcute coronary syndrome
Indication DetailsTreat acute coronary syndrome (ACS)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$23.8M

$1.8M

$22.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today